Enzalutamide - Astellas Pharma/Medivation

Drug Profile

Enzalutamide - Astellas Pharma/Medivation

Alternative Names: ASP 9785; MDV 3100; Xtandi

Latest Information Update: 06 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of California at Los Angeles; University of Texas M. D. Anderson Cancer Center
  • Developer Astellas Pharma; H. Lee Moffitt Cancer Center and Research Institute; M. D. Anderson Cancer Center; Medivation; National Cancer Institute (USA); Queen Mary University of London; The Prostate Cancer Clinical Trials Consortium; University of California, Davis; University of Chicago
  • Class Antineoplastics; Benzamides; Fluorobenzenes; Imidazolidines; Nitriles; Small molecules; Thiones
  • Mechanism of Action Androgen receptor antagonists; Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Prostate cancer
  • Phase II Endometrial cancer; Hepatocellular carcinoma; Salivary gland cancer
  • Phase I Pancreatic cancer
  • Discontinued Breast cancer

Most Recent Events

  • 16 Nov 2017 Astellas Pharma, Clovis Oncology and Bristol-Myers Squibb plan a phase II trial for Prostate cancer (Metastatic disease, Combination therapy) in USA, Argentina, Australia, Brazil, Chile and Germany in November 2017 (NCT03338790)
  • 06 Nov 2017 Enzalutamide is still in phase I trial for Pancreatic-cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in USA (NCT02138383)
  • 06 Nov 2017 Astellas Pharma plans a clinical trial for Prostate cancer (Metastatic disease, Second-line therapy or greater) in Sweden in December 2017 (NCT03328364)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top